
|Articles|November 1, 1997
The American Journal of Managed Care
- November 1997
- Volume 3
- Issue 11
When Is a Cost-Effectiveness Claim Valid? How Much Should the FDA Care?
Advertisement
Articles in this issue
almost 29 years ago
Empiric Examination of Physician Behavior in a Changing Healthcare Marketalmost 29 years ago
Healthcare Utilization Among Women with Eating Disordered Behavioralmost 29 years ago
Postpartum Depressionalmost 29 years ago
Pharmaceutical Considerations of Common Herbal Medicinealmost 29 years ago
Treatment Patterns for Heart Failure in a Primary Care Environmentalmost 29 years ago
Enhancement of Compliance Among Patients with HypertensionAdvertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer
2
Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD
3
FDA Panel Backs 6 Peptides for Compounding
4
Expanding Community Access to CAR T, Bispecific Therapies in Multiple Myeloma: Peter Forsberg, MD
5




